全球迷走神經刺激市場：依產品、生物材料、應用、地區、範圍和預測

全球迷走神經刺激市場規模及預測

2024 年全球迷走神經刺激市場規模價值 106.7 億美元，預計到 2031 年將達到 237.3 億美元，2024 年至 2031 年的複合年增長率為 10.50%。迷走神經刺激 (VNS) 是一種神經調節療法，它會向迷走神經發送電脈衝來治療多種疾病，包括癲癇和憂鬱症。這種治療方法可以調節神經通路和神經傳導物質的釋放，從而改善情緒並減少癲癇發作頻率。

VNS 的應用範圍已不僅限於癲癇和憂鬱症，目前研究也在探索其在治療焦慮症、慢性疼痛和發炎性疾病方面的潛力。

技術的進步和對神經迴路的理解可能會帶來更精確、更有效的刺激方法、個人化治療和非侵入性替代方法的開發，最終改善患者的治療效果，因為它將改善治療效果並擴大各種健康問題的治療選擇。

全球迷走神經刺激市場動態

主要市場驅動因子

神經系統疾病發生率不斷上升：

癲癇和憂鬱症等神經系統疾病的發生率不斷上升，推動了對 VNS 的需求。根據世界衛生組織 (WHO) 的數據，全球約有 5,000 萬人患有癲癇，其中近 30% 患有難治性癲癇，這增加了對替代療法的需求。

神經調節療法的傳播：

醫療保健提供者對神經調節療法的接受度不斷提高，從而推動了市場的成長。根據美國國立衛生研究院的報告，包括 VNS 在內的神經調節技術反映了向創新治療方法的轉變，全球約有一百萬名患者採用了這些技術。

VNS 設備的技術進步：

VNS 技術的不斷進步，包括小型化和設備功效的提高，正在改善患者的治療效果。美國食品藥物管理局 (FDA) 報告稱，神經調節療法設備批准的年增長率為 6.5%，顯示 VNS 創新管道強勁。

增加醫療支出：

醫療保健支出的增加正在推動對包括 VNS 設備在內的先進醫療技術的投資。根據美國醫療保險和醫療補助服務中心 (CMS) 的數據，美國的醫療保健支出預計到 2028 年將達到 6.2 兆美元，這為 VNS 和其他神經調節療法的發展創造了肥沃的環境。

主要問題

設備和程式成本高

VNS 設備和植入程序的高成本可能會限制其可近性，尤其是對於低收入地區的患者。這一經濟障礙影響了 VNS 治療的採用率。

對醫療保健提供者的認知有限

一些醫療保健提供者仍然缺乏對VNS的認識和理解，這可能會阻止他們將其推薦為治療選擇。需要進行教育工作來增加人們對這種治療益處的認識和理解。

患者反應

並非所有患者對 VNS 的反應都很好，且治療結果也各不相同。這種不一致使得醫療保健提供者和患者對治療的有效性產生不確定性。

監理障礙

醫療器材監管環境複雜且耗時。監管課題可能會延遲新 VNS 技術的批准，從而影響市場成長和創新。

主要趨勢：

轉變為非侵入性 VNS 的

非侵入性迷走神經刺激 (VNS) 方法的發展趨勢日益明顯，例如經皮迷走神經刺激，它可以為患者提供一種比傳統手術更簡單、風險更低的替代方法。

整合人工智慧

將人工智慧和機器學習融入 VNS 系統可以根據個別患者數據實現更個人化的刺激參數，從而有可能提高治療效果。

擴展到新的適應症

越來越多的研究正在探討迷走神經刺激(VNS) 對一系列疾病的治療潛力，這些疾病不僅包括癲癇和憂鬱症，還包括焦慮症、偏頭痛和發炎性疾病，從而擴大了這種治療方法的應用範圍。

聯合研究計畫

學術機構、醫療保健提供者和行業利益相關者之間的合作正在增加，透過共享知識和資源來促進創新和新 VNS 技術和治療方案的開發。

目錄

第 1 章全球迷走神經刺激市場：簡介

市場概況
• 研究範圍
• 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

• 資料探勘
• 驗證
• 主要來源
• 資料來源列表

第 4 章迷走神經刺激的全球市場展望

• 概述
• 市場動態
  • 驅動程式
  • 阻礙因素
  • 機會

第5章 全球迷走神經刺激市場（依產品）

• 概述
• 植入式迷走神經刺激裝置
• 外部 VNS 設備

第6章全球迷走神經刺激市場（依生物材料）

• 概述
• 聚合物
• 金屬
• 陶瓷

第7章 全球迷走神經刺激市場（按應用）

• 概述
• 憂鬱症
• 偏頭痛
• 癲癇
• 其他

第8章 全球迷走神經刺激市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
  亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

第 9 章迷走神經刺激市場：競爭格局

• 概述
• 各公司的市場排名
• 主要發展策略

第10章 公司簡介

• LivaNova Plc.
• Medtronic Plc.
• EnteroMedics Inc.
• ElectroCore LLC
• Boston Scientific Corporation
• NeuroPace Inc
• BioControl Medical
• Bioness Inc.
• Nevro Corporation
• Aleva Neurotherapeutics SA.

第 11 章附錄

• 相關研究

Global Vagus Nerve Stimulation Market Size and Forecast

The Global Vagus Nerve Stimulation Market size was valued at USD 10.67 Billion in 2024 and is projected to reach USD 23.73 Billion by 2031 , growing at a CAGR of 10.50% from 2024 to 2031. Global Vagus Nerve Stimulation (VNS) is a neuromodulation therapy that involves delivering electrical impulses to the vagus nerve to treat various medical conditions, particularly epilepsy and depression. This technique works by modulating neural pathways and neurotransmitter release, which can lead to improved mood and reduced seizure frequency.

The application of VNS has expanded beyond epilepsy and depression, with research exploring its potential in treating conditions such as anxiety disorders, chronic pain, and inflammatory diseases.

The future of Global VNS looks promising, as advancements in technology and understanding of neural circuits could lead to more precise and effective stimulation methods, personalized therapies, and non-invasive alternatives, ultimately enhancing patient outcomes and expanding treatment options for diverse health challenges.

Global Vagus Nerve Stimulation Market Dynamics

The key market dynamics that are shaping the global vagus nerve stimulation market include:

Key Market Drivers:

Increasing Prevalence of Neurological Disorders:

The rising incidence of neurological disorders such as epilepsy and depression drive the demand for VNS. According to the World Health Organization (WHO), approximately 50 million people worldwide have epilepsy, with nearly 30% of these individuals experiencing drug-resistant seizures, highlighting a significant need for alternative treatments.

Growing Adoption of Neuromodulation Therapies:

The increasing acceptance of neuromodulation therapies among healthcare providers is propelling market growth. A report from the National Institute of Health estimated that neuromodulation techniques, including VNS, have been adopted in about 1 million patients globally, reflecting a shift toward innovative therapeutic approaches.

Technological Advancements in VNS Devices:

Continuous advancements in VNS technology, such as miniaturization and improvements in device efficacy, are enhancing patient outcomes. The U.S. Food and Drug Administration (FDA) reported a 6.5% annual growth rate in device approvals for neuromodulation therapies, indicating a robust pipeline for VNS innovations.

Rising Healthcare Expenditure:

Increased healthcare expenditure is driving investments in advanced medical technologies, including VNS devices. According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is projected to reach $6.2 trillion by 2028, which fosters an environment conducive to the growth of VNS and other neuromodulation therapies.

Key Challenges:

High Cost of Devices and Procedures

: The high cost associated with VNS devices and implantation procedures can limit accessibility for patients, especially in low-income regions. This financial barrier affects the adoption rate of VNS therapies.

Limited Awareness Among Healthcare Providers

: There is still a lack of awareness and understanding of VNS among some healthcare providers, which can hinder its recommendation as a treatment option. Educational initiatives are needed to enhance knowledge and understanding of the therapy's benefits.

Variable Patient Response

: Not all patients respond favorably to VNS, leading to variability in treatment outcomes. This inconsistency can create uncertainty among healthcare providers and patients regarding the effectiveness of the therapy.

Regulatory Hurdles

: Navigating the regulatory landscape for medical devices can be complex and time-consuming. Regulatory challenges may delay the approval of new VNS technologies, impacting market growth and innovation.

Key Trends:

Shift Towards Non-Invasive VNS

: There is a growing trend toward developing non-invasive VNS methods, such as transcutaneous vagus nerve stimulation, which can provide patients with easier and less risky alternatives to traditional surgical options.

Integration of Artificial Intelligence

: The incorporation of artificial intelligence and machine learning into VNS systems is emerging, allowing for more personalized stimulation parameters based on individual patient data, which could enhance treatment efficacy.

Expansion into New Indications

: Research is increasingly exploring the potential of VNS for various conditions beyond epilepsy and depression, including anxiety, migraine, and inflammatory diseases, indicating a broader application scope for this therapy.

Collaborative Research Initiatives

: Collaborative efforts among academic institutions, healthcare providers, and industry stakeholders are on the rise, fostering innovation and the development of new VNS technologies and treatment protocols through shared knowledge and resources.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Vagus Nerve Stimulation Market Regional Analysis

Here is a more detailed regional analysis of the global vagus nerve stimulation market:

North America:

North America holds a dominant position in the global vagus nerve stimulation market, accounting for a significant share due to advanced healthcare infrastructure and high adoption of innovative medical technologies. The presence of key players, robust research and development activities, and strong support from healthcare policies further contribute to the market's growth in this region. According to the U.S. Centers for Disease Control and Prevention (CDC), the prevalence of neurological disorders, which can be treated with vagus nerve stimulation, is expected to rise, enhancing the demand for such therapeutic interventions.

Moreover, the increasing incidence of epilepsy and depression, conditions where vagus nerve stimulation has proven effective, drives the market in North America. The National Institute of Neurological Disorders and Stroke (NINDS) reported that approximately 1 in 26 individuals will develop epilepsy at some point in their lives, indicating a significant patient population that could benefit from these treatments. This substantial demand for effective management solutions has led to higher investments in vagus nerve stimulation technology by both healthcare providers and pharmaceutical companies.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for vagus nerve stimulation. Factors such as the increasing prevalence of neurological disorders, growing awareness of advanced treatment options, and a rapidly expanding healthcare sector drive this growth. According to the World Health Organization (WHO), Asia Pacific is home to over 60% of the global population, highlighting a substantial potential market for innovative medical treatments.

The region is experiencing a surge in investment in healthcare infrastructure, with governments actively promoting advanced medical technologies. For instance, the Indian government has initiated various healthcare reforms aimed at improving access to cutting-edge treatments, including those for neurological disorders. According to a report from the Ministry of Health and Family Welfare, investments in mental health and neurological care are projected to grow by 20% annually, supporting the increased adoption of vagus nerve stimulation therapies across the region.

Global Vagus Nerve Stimulation Market: Segmentation Analysis

The Global Vagus Nerve Stimulation Market is segmented on the basis of By Product, By Biomaterial, By Application, and By Geography.

Global Vagus Nerve Stimulation Market, By Product

• Implantable VNS Devices
• External VNS Devices

Based on Product, the Global Vagus Nerve Stimulation Market is segmented into Implantable VNS Devices and External VNS Devices. Implantable VNS Devices is the dominating segment due to their established efficacy and long-term therapeutic benefits, particularly for conditions such as epilepsy and treatment-resistant depression. However, the fastest-growing segment is the external VNS devices, primarily driven by their non-invasive nature, ease of use, and growing consumer preference for less invasive treatment options.

Global Vagus Nerve Stimulation Market, By Biomaterial

• Polymerics
• Metallics
• Ceramics

Based on Biomaterial, the Global Vagus Nerve Stimulation Market is segmented into Polymerics, Metallics, and Ceramics. The Polymerics is the dominating segment due to its versatile applications across various industries, including automotive, packaging, and consumer goods, driven by properties such as lightweight, corrosion resistance, and cost-effectiveness. However, the ceramics segment is recognized as the fastest-growing segment, largely attributed to the increasing demand for advanced ceramics in applications such as electronics, healthcare, and aerospace, where their high thermal stability and mechanical strength are essential.

Global Vagus Nerve Stimulation Market, By Application

• Depression
• Migraine
• Epilepsy

Based on Application, the Global Vagus Nerve Stimulation Market is segmented into Depression, Migraine, and Epilepsy. The Epilepsy is the dominating segment due to its established application in treating drug-resistant epilepsy, supported by robust clinical evidence and FDA approval for VNS devices. However, the fastest-growing segment is depression, as there is increasing recognition of VNS as an effective treatment for treatment-resistant depression.

Global Vagus Nerve Stimulation Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Vagus Nerve Stimulation Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region, accounting for a significant share due to advanced healthcare infrastructure and high adoption of innovative medical technologies. Asia Pacific region is the fastest-growing market for vagus nerve stimulation. Factors such as the increasing prevalence of neurological disorders, growing awareness of advanced treatment options, and a rapidly expanding healthcare sector drive this growth.

Key Players

• The "Global Vagus Nerve Stimulation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market
• LivaNova Plc., Medtronic Plc., EnteroMedics Inc., ElectroCore LLC, Boston Scientific Corporation, NeuroPace Inc, BioControl Medical, Bioness Inc., Nevro Corporation, and Aleva Neurotherapeutics SA.
• Our
• market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
• Global Vagus Nerve Stimulation Market: Recent Developments
• In August 2024 ElectroCore, Inc. announced the acquisition of a complementary neuromodulation technology company to enhance its product portfolio in the vagus nerve stimulation market.
• In July 2024 LivaNova PLC received FDA approval for the expanded use of its Vagus Nerve Stimulator (VNS) device for treatment-resistant depression.
• In June 2024 NeuroMetrix, Inc. announced positive results from a clinical study evaluating the efficacy of its non-invasive vagus nerve stimulation device for chronic pain management.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VAGUS NERVE STIMULATION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VAGUS NERVE STIMULATION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities

5 GLOBAL VAGUS NERVE STIMULATION MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Implantable VNS Devices
• 5.3 External VNS Devices

6 GLOBAL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL

• 6.1 Overview
• 6.2 Polymerics
• 6.3 Metallics
• 6.4 Ceramics

7 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Depression
• 7.3 Migraine
• 7.4 Epilepsy
• 7.5 Others

8 GLOBAL VAGUS NERVE STIMULATION MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL VAGUS NERVE STIMULATION MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 LivaNova Plc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Medtronic Plc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 EnteroMedics Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 ElectroCore LLC
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Boston Scientific Corporation
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 NeuroPace Inc
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 BioControl Medical
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bioness Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Nevro Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Aleva Neurotherapeutics SA.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research